Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Onasemnogene Abeparvovec · Itvisma, Zolgensma

Gene therapy (AAV vector) · Gene replacement: spinal muscular atrophy with bi-allelic SMN1 mutations · developed by Novartis Innovative Technologies

Approved FDA, Nov 2025
NVS Developer

What is Onasemnogene Abeparvovec?

Onasemnogene abeparvovec is an AAV9-based gene therapy that delivers a copy of the human SMN1 gene encoding the survival of motor neuron (SMN) protein, which is insufficiently expressed in spinal muscular atrophy caused by bi-allelic SMN1 mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Itvisma, Zolgensma, AVXS-101, (ITVISMA)
Drug type
Gene therapy (AAV vector)
Targets
spinal muscular atrophy with bi-allelic SMN1 mutations (biomarker)
Mechanism
Gene replacement: spinal muscular atrophy with bi-allelic SMN1 mutations
Therapy area
Neurology
Developer
Novartis Innovative Technologies Inc. (NVS)
FDA status
Approved as Itvisma, Zolgensma (November 24, 2025), BLA125694 · FDA label
UNII
MLU3LU3EVV

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 16, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Spinal Muscular Atrophy

More from Novartis Innovative Technologies

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Onasemnogene Abeparvovec

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.